# IGC Pharma, Inc.: overview IGC · NYSE · CIK 1326205 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/igc.md) · [Financials](/companies/igc/financials.md) · [Filings](/companies/igc/filings.md) · [Insiders](/companies/igc/insiders.md) Latest reported revenue: [$265.0k](/filings/0001185185-26-003544.md) for Q2 FY2027, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:Revenues, accession 0001185185-26-003544). ## Last eight quarters | Line item | Unit | Q2 FY2025 (2024-09-30) | Q3 FY2025 (2024-12-31) | Q4 FY2025 (2025-03-31) | Q1 FY2026 (2025-06-30) | Q2 FY2026 (2025-09-30) | Q3 FY2026 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2027 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [412](/filings/0001185185-25-001752.md) | [257](/filings/0001185185-25-000137.md) | [330](/filings/0001185185-26-001885.md) | [328](/filings/0001185185-26-003544.md) | [191](/filings/0001185185-25-001752.md) | [350 d](/filings/0001185185-26-000941.md) | [317](/filings/0001185185-26-001885.md) | [265](/filings/0001185185-26-003544.md) | | Gross margin | % | [48.1%](/filings/0001185185-25-001752.md) | [40.5%](/filings/0001185185-25-000137.md) | [46.7%](/filings/0001185185-26-001885.md) | [47.0%](/filings/0001185185-26-003544.md) | [51.8%](/filings/0001185185-25-001752.md) | [12.6% d](/filings/0001185185-26-000941.md) | [17.4%](/filings/0001185185-26-001885.md) | [18.1%](/filings/0001185185-26-003544.md) | | Operating margin | % | [(427.2%)](/filings/0001185185-25-001752.md) | [(730.7%)](/filings/0001185185-25-000137.md) | [(428.2%)](/filings/0001185185-26-001885.md) | [(580.8%)](/filings/0001185185-26-003544.md) | [(1517.8%)](/filings/0001185185-25-001752.md) | [(840.3%) d](/filings/0001185185-26-000941.md) | [(775.4%)](/filings/0001185185-26-001885.md) | [(1050.6%)](/filings/0001185185-26-003544.md) | | Net margin | % | [(416.7%)](/filings/0001185185-25-001752.md) | [(711.7%)](/filings/0001185185-25-000137.md) | [(363.0%)](/filings/0001185185-26-001885.md) | [(487.5%)](/filings/0001185185-26-003544.md) | [(953.4%)](/filings/0001185185-25-001752.md) | [(207.4%) d](/filings/0001185185-26-000941.md) | [(757.7%)](/filings/0001185185-26-001885.md) | [(1107.9%)](/filings/0001185185-26-003544.md) | | Diluted EPS | $ per share | [(0.02)](/filings/0001185185-25-001752.md) | [(0.02)](/filings/0001185185-25-000137.md) | [(0.02)](/filings/0001185185-26-001885.md) | [(0.02)](/filings/0001185185-26-003544.md) | [(0.02)](/filings/0001185185-25-001752.md) | not reported | [(0.02)](/filings/0001185185-26-001885.md) | [(0.03)](/filings/0001185185-26-003544.md) | | Free cash flow | $k | [(1,025) d](/filings/0001185185-25-001752.md) | [(1,344) d](/filings/0001185185-26-000941.md) | [(748)](/filings/0001185185-26-001885.md) | [(1,415)](/filings/0001185185-25-000997.md) | [(2,119) d](/filings/0001185185-25-001752.md) | [(1,235) d](/filings/0001185185-26-000941.md) | [(1,224)](/filings/0001185185-26-001885.md) | [(1,355) d](/filings/0001185185-26-003544.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 9-month figure less the 6-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-03-31) | FY2022 (2022-03-31) | FY2023 (2023-03-31) | FY2024 (2024-03-31) | FY2025 (2025-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.9](/filings/0001185185-22-000768.md) | [0.4](/filings/0001185185-23-000693.md) | [0.9](/filings/0001185185-24-000650.md) | [1.3](/filings/0001185185-25-000706.md) | [1.3](/filings/0001185185-26-000941.md) | | Gross margin | % | [12.6%](/filings/0001185185-22-000768.md) | [48.9%](/filings/0001185185-23-000693.md) | [48.5%](/filings/0001185185-24-000650.md) | [54.5%](/filings/0001185185-25-000706.md) | [48.7%](/filings/0001185185-26-000941.md) | | Operating margin | % | [(971.5%)](/filings/0001185185-22-000768.md) | [(3886.1%)](/filings/0001185185-23-000693.md) | [(1270.1%)](/filings/0001185185-24-000650.md) | [(728.5%)](/filings/0001185185-25-000706.md) | [(585.8%)](/filings/0001185185-26-000941.md) | | Net margin | % | [(981.2%)](/filings/0001185185-22-000768.md) | [(3782.4%)](/filings/0001185185-23-000693.md) | [(1263.0%)](/filings/0001185185-24-000650.md) | [(966.5%)](/filings/0001185185-25-000706.md) | [(560.3%)](/filings/0001185185-26-000941.md) | | Diluted EPS | $ per share | [(0.21)](/filings/0001185185-21-000802.md) | not reported | not reported | [(0.22)](/filings/0001185185-25-000706.md) | [(0.09)](/filings/0001185185-26-000941.md) | | Free cash flow | $m | [(12.3)](/filings/0001185185-22-000768.md) | [(7.7)](/filings/0001185185-23-000693.md) | [(7.4)](/filings/0001185185-24-000650.md) | [(5.3)](/filings/0001185185-25-000706.md) | [(4.9)](/filings/0001185185-26-000941.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/igc/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $239.2k | 879,394 | | Reduced −163,990 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $221.7k | 814,914 | | Added +96,478 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $191.4k | 703,798 | | Unchanged | | [AdvisorShares Investments LLC](/funds/1425930.md) | 2026-06-30 | $184.5k | 678,480 | | New +678,480 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $119.0k | 437,317 | | New +437,317 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $114.1k | 419,413 | | Added +3,525 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $78.0k | 286,608 | | Reduced −197,367 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $54.6k | 200,799 | | Unchanged | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $46.3k | 170,274 | | Added +56,867 | | [LAWOOD & CO](/funds/2109484.md) | 2026-06-30 | $20.4k | 75,000 | | Unchanged | ## Recent filings [All 638 filings](/companies/igc/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 00:32 ET | [DEF 14A](/filings/0001185185-26-004896.md) | Proxy statement, period 2026-12-02 | 0001185185-26-004896 | | 2026-08-14 | 20:01 ET | [10-Q](/filings/0001185185-26-003544.md) | Quarterly report, period 2026-06-30 | 0001185185-26-003544 | | 2026-07-14 | 22:11 ET | [8-K](/filings/0001185185-26-002922.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001185185-26-002922 | | 2026-07-06 | 20:02 ET | [8-K](/filings/0001185185-26-002808.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-26-002808 | | 2026-06-08 | 20:03 ET | [8-K](/filings/0001185185-26-002410.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001185185-26-002410 | | 2026-05-15 | 20:02 ET | [10-Q](/filings/0001185185-26-001885.md) | Quarterly report, period 2026-03-31 | 0001185185-26-001885 | | 2026-04-20 | 20:01 ET | [8-K](/filings/0001185185-26-001437.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-26-001437 | | 2026-03-30 | 21:43 ET | [8-K](/filings/0001185185-26-001146.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001185185-26-001146 | | 2026-03-12 | 22:19 ET | [8-K](/filings/0001185185-26-000846.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001185185-26-000846 | | 2026-01-06 | 23:11 ET | [8-K](/filings/0001185185-26-000032.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001185185-26-000032 | ## Latest annual report [Form 10-K for the fiscal year ended Mar 31, 2025](/filings/0001185185-25-000706.md), filed Jun 27, 2025. ## Forecast league Q3 FY2027, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/52fc9efc-0870-46fc-83bc-f628454b73f6) ## About the filer - CIK: 1326205 - Tickers: IGC - Exchange: NYSE - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: MD - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.